Stay updated with breaking news from ஏஞ்சலா மார்குசி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
DBV Technologies S.A.: Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
DBV Technologies S.A.: DBV Technologies Reports Second Quarter 2021 Financial Results and Recent Business Developments finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
DBV Technologies S.A.: DBV Technologies to Report First Half 2021 Financial Results and Business Updates on August 2, 2021 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
DBV Technologies S.A.: DBV Technologies Announces Results of its 2021 Ordinary and Extraordinary General Meeting and the Appointment of Dr. Adora Ndu, Pharm.D., J.D., and Dr. Ravi Madduri Rao, M.D., Ph.D., as Members of its Board of Directors DBV Technologies Announces Results of its 2021 Ordinary and Extraordinary General Meeting and Madduri mbers of its Board of Directors DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today held its Ordinary and Extraordinary General Meeting. DBV Technologies General Meeting was chaired by Michel de Rosen, Chairman of DBV Technologies Board of Directors, in a closed virtual session without the physical presence of shareholders or any other person authorized to attend, at DBV Technologies registered office. ....
DBV Technologies S.A.: DBV Technologies Announces Filing of its First Form 10-Q for the First Quarter of 2021 DBV Technologies Announces Filing of its 2021 DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the filing of its first Form 10-Q for the quarter ended March 31, 2021 with the U.S. Securities and Exchange Commission (SEC). This document can be accessed on the Investors & Media section of the Company s website at www.dbv-technologies.com. In addition, this Form 10-Q is available on the SEC s website at www.sec.gov. About DBV Technologies DBV Technologies is developing Viaskin, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT, DBV s method of delivering biologically active compounds to the immune system through intact skin. With this new class ....